Moreover, these results have been further substantiated by analyzing public databases from The Cancer Genome Atlas data portal and from the MSKCC dataset, which indicate that EN2 is overexpressed in different cohorts of PCa patients and; therefore, suggest the universality of this biomarker. This evidence concerns the gene EN2 and posterior cortical atrophy.